Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$898.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dipal Doshi
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 152
- Beta
- -0.24
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.06
Financials
Revenue
$898.0K-96.4%Net Income
$-42.76MEBITDA
$-41.89MFree Cash Flow
$-32.47MEPS (diluted)
$-1.01Shares Outstanding (diluted)
42.22M+3928.7%Operating Expenses
$45.86MCash & Debt
$223.00MRevenue by Segment (annual)
$300.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $25.42M | $-143.75M | $-3.47 |
| 2024 | $210.78M | $65.63M | $1.76 |
| 2023 | $129.01M | $-6.68M | $-0.20 |
| 2022 | $0.00 | $-94.62M | $-2.79 |
| 2021 | $0.00 | $-51.16M | $-1.60 |
| 2020 | $0.00 | $-26.52M | $-0.84 |
| 2019 | $0.00 | $-4.65M | $-4.44 |
Valuation
TRDAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·6h ago·Neutral
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics.
View source ↗ - Newsglobenewswire.com·7d ago·Neutral
…2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiating Cohort 3 at the…
View source ↗ - Newsseekingalpha.com·11d ago·Negative
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from $5.61, driven by potential validation of its EEV platform. ENTR-601-44's initial dystrophin increase was disappointing, but lower pediatric drug exposure provides a plausible, testable explanation; higher dosing results are expected in Q1 2027. Valuation is anchored by risk-adjusted pipeline estimates and significant cash reserves, w
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
…pport projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystrophy community who are currently underrepresented or underserved.
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-0.98 per share
Typical surprise +10.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-1.01 vs $-1.05beat
- Thu, May 7$-0.95 vs $-1.06beat
- Thu, Feb 26$-0.94 vs $-1.32beat
- Thu, Nov 6$-1.06 vs $-1.04miss
- Wed, Aug 6$-1.04 vs $-0.86miss
- Thu, May 8$-0.42 vs $-0.78beat
Estimates and results for TRDA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TRDA officers and directors.
- Bought
- $1.6m
- Sold
- $16.2m
17 trades
51 trades
- Mpm Bioventures 2018, L.p.sold
- Mpm Bioventures 2014, L.p.sold
- Mpm Bioventures 2018, L.p.sold
- Mpm Bioventures 2014, L.p.sold
- Mpm Bioventures 2018, L.p.sold
- Mpm Bioventures 2014, L.p.sold
- Mpm Bioventures 2018, L.p.sold
- Mpm Bioventures 2014, L.p.sold
32 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TRDA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.